<DOC>
	<DOCNO>NCT00303563</DOCNO>
	<brief_summary>This 4 arm study compare safety efficacy , regard reduction sign symptom , P38 Inhibitor ( 4 ) ( 50 , 150 300mg po qd ) monotherapy versus methotrexate monotherapy adult patient active rheumatoid arthritis . Patients randomize receive one 3 dos P38 Inhibitor ( 4 ) methotrexate . The anticipated time study treatment &lt; 3 month , target sample size 100-500 individual .</brief_summary>
	<brief_title>A Study P38 Inhibitor ( 4 ) Monotherapy Patients With Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>adult patient &gt; 18 year age , active RA ; receive treatment RA outpatient basis ; female childbearing potential , nonsterilized male partner childbearing potential , must use reliable contraception , 4 week , study . major surgery within 8 week prior screen ; rheumatic autoimmune disease inflammatory joint disease RA ; treatment methotrexate within 8 week baseline ; concurrent use DMARDs , include antiTNF biologic therapy RA .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>